Improvements in survival for glioblastoma in the post-Stupp protocol era
Neuro-Oncology · 14.10.2025 · 27 (9) · 2484-2486
DOI: 10.1093/neuonc/noaf134 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Neuro-Oncology, online erschienen am 23.07.2025. Verfasst von Mackenzie Price und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novocure.
Abstract (Originalsprache)
Survival after glioblastoma diagnosis is poor1 and treatment-dependent (overall median survival of 9 months, 14 months when receiving resection and chemoradiation).1,2 A significant increase in median survival occurred after the introduction of the Stupp protocol (2004), which specified first-line treatment with concurrent radiation and temozolomide.2,3 Several studies have observed a continuing upward trend in survival since the introduction of this protocol.4 This improvement may be due to new treatments, such as bevacizumab (approved 2009 for recurrent glioblastoma), immunotherapy (in clinical trials), or Tumor Treating Fields (TTFields) (approved 2011 for recurrent glioblastoma, newly diagnosed glioblastoma in 2015). We used a population-based dataset to verify this longitudinal improvement in survival, and an insurance claims dataset to understand potential associated treatment factors. Provider-side claims data were obtained from IQVIA Oncology EMR (>1.1 million oncology patients across 41 states) for adults (18+ years) diagnosed with a malignant brain tumor (ICD-9/ICD-10:191.0-191.9/C71.0-C71.9) from 2015 to 2021 who received biopsy/resection and temozolomide within 60 days of diagnosis (radiation not included due to high levels of missing claims). Individuals were excluded if treated with chemotherapeutic agents used in other malignancies or if they had a pre-existing code for a non-brain primary tumor to eliminate misclassified brain metastases. Treatment was determined using ICD-9/ICD-10 and HCPCS/CPT procedure codes. Comorbidity scores were calculated using ICD-9/ICD-10 codes within 60 days of the initial diagnosis using Elixhauser comorbidity weights. Date of death was estimated by CPT codes 99238 or 99239, or the date of the last claim followed by 2 months minimum of no claims prior to the end of follow-up. Survival was quantified via Kaplan–Meier estimation for the whole cohort and for a subset who received radiation. Cox proportional hazards models estimated the effect of treatment on survival, adjusted for age, sex, comorbidity score, TTFields, and bevacizumab. Population-based survival data from the National Program of Cancer Registries (NPCR) from 2004 to 2020 (~82% of the US population) adult (18+ years) pathology-confirmed cases (ICD-O-3 histology codes 9440/3–9442/3) receiving surgery and radiation treatment (chemotherapy not included due to high levels of missing data) was used to assess survival trends. Median survival was estimated using Kaplan–Meier regression overall and by time periods in NPCR. There were 18 883 and 110 610 cases meeting inclusion criteria in IQVIA (median age 63) and NPCR (median age 62) (see Figure 1A for a summary of patient characteristics by dataset). Median survival was 13.9 months in IQVIA and 14.0 months in NPCR. This increased in NPCR from 13 months in 2004–2006 (Stupp integration) to 15 months in 2017–2020 (late post-Stupp; Figure 1B), and with a significant downward trend in hazard ratios (HRs) with increasing year of diagnosis (p-trend:
Autor:innen und Institutionen
- Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
- Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.
- The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.
- Novocure, New York, New York, USA.
- Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
- Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, Maryland, USA.
ORCID-Profile: Mackenzie Price, Justin T Low, Carol Kruchko, Gino Cioffi, Kristin A Waite, Jill S Barnholtz-Sloan, Quinn T Ostrom
Förderung
- Novocure
Zitieren
APA
Price, M., Low, J. T., Chavez, G., Conlon, P., Avgeropoulos, N., Kruchko, C., Cioffi, G., Waite, K. A., Barnholtz-Sloan, J. S., & Ostrom, Q. T. (2025). Improvements in survival for glioblastoma in the post-Stupp protocol era. Neuro-Oncology, 27(9), 2484-2486. https://doi.org/10.1093/neuonc/noaf134
Vancouver
Price M, Low JT, Chavez G, Conlon P, Avgeropoulos N, Kruchko C, et al. Improvements in survival for glioblastoma in the post-Stupp protocol era. Neuro-Oncology. 2025;27(9):2484-2486. doi:10.1093/neuonc/noaf134
BibTeX
@article{Price2025,
author = {Price, Mackenzie and Low, Justin T and Chavez, Gordon and Conlon, Patrick and Avgeropoulos, Nick and Kruchko, Carol and Cioffi, Gino and Waite, Kristin A and Barnholtz-Sloan, Jill S and Ostrom, Quinn T},
title = {Improvements in survival for glioblastoma in the post-Stupp protocol era},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {9},
pages = {2484--2486},
doi = {10.1093/neuonc/noaf134}
}
EUVIMED